April 15, 2024 11:10 AM EDT
News Briefing

Mus­tang Bio to lay off work­ers; MaaT's new da­ta for mi­cro­bio­me ther­a­py

ENDPOINTS

Mus­tang Bio ax­es 81% of staffers: The CAR-T cell ther­a­py com­pa­ny plans to im­ple­ment a work­force re­duc­tion through­out April to pre­serve cash in the sec­ond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times